BG108490A - 5-заместени-2-арилпиридини като модулатори на crf1 - Google Patents

5-заместени-2-арилпиридини като модулатори на crf1 Download PDF

Info

Publication number
BG108490A
BG108490A BG108490A BG10849003A BG108490A BG 108490 A BG108490 A BG 108490A BG 108490 A BG108490 A BG 108490A BG 10849003 A BG10849003 A BG 10849003A BG 108490 A BG108490 A BG 108490A
Authority
BG
Bulgaria
Prior art keywords
alkyl
alkoxy
amino
independently selected
mono
Prior art date
Application number
BG108490A
Other languages
Bulgarian (bg)
English (en)
Inventor
Ping Ge
Taeyoung Yoon
Lu Zhang
Raymond Horvath
Original Assignee
Neurogen Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corporation filed Critical Neurogen Corporation
Publication of BG108490A publication Critical patent/BG108490A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
BG108490A 2001-05-22 2003-12-22 5-заместени-2-арилпиридини като модулатори на crf1 BG108490A (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29270301P 2001-05-22 2001-05-22

Publications (1)

Publication Number Publication Date
BG108490A true BG108490A (bg) 2005-01-31

Family

ID=23125823

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108490A BG108490A (bg) 2001-05-22 2003-12-22 5-заместени-2-арилпиридини като модулатори на crf1

Country Status (20)

Country Link
US (2) US7223778B2 (enExample)
EP (1) EP1392302A1 (enExample)
JP (1) JP2004531570A (enExample)
KR (1) KR20040015716A (enExample)
AP (1) AP2003002920A0 (enExample)
BG (1) BG108490A (enExample)
BR (1) BR0209920A (enExample)
CA (1) CA2448198A1 (enExample)
EC (1) ECSP034860A (enExample)
HR (1) HRP20031056A2 (enExample)
HU (1) HUP0400316A2 (enExample)
IL (1) IL158958A0 (enExample)
IS (1) IS7046A (enExample)
MX (1) MXPA03010692A (enExample)
NO (1) NO20035183D0 (enExample)
PL (1) PL367153A1 (enExample)
RU (1) RU2003134010A (enExample)
SK (1) SK15432003A3 (enExample)
TN (1) TNSN03119A1 (enExample)
WO (1) WO2002096421A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
AU2003291403A1 (en) * 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
WO2005007627A1 (ja) * 2003-07-18 2005-01-27 Nihon Nohyaku Co., Ltd. フェニルピリジン誘導体、その中間体及びこれを有効成分とする除草剤
JPWO2005040135A1 (ja) * 2003-10-24 2007-03-08 小野薬品工業株式会社 抗ストレス薬およびその医薬用途
RU2423979C2 (ru) * 2005-06-17 2011-07-20 АФТ Фармасьютикалз Лимитед Новая фармацевтическая композиция и ее применение в способе лечения пациентов с гиперемией и отеком слизистой оболочки верхних дыхательных путей
PT2404919E (pt) 2005-11-08 2013-10-22 Vertex Pharma Composto heterocíclico útil como um modulador de transportadores de cassete de ligação a atp
EP2164840A2 (en) 2007-05-09 2010-03-24 Vertex Pharmaceuticals Incorporated Modulators of cftr
ATE554070T1 (de) * 2007-08-01 2012-05-15 Taisho Pharmaceutical Co Ltd Hemmer der s1p1-bindung
CA2989620C (en) * 2007-12-07 2022-05-03 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
HUE049642T2 (hu) 2007-12-07 2020-09-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái
AU2013205160B2 (en) * 2007-12-07 2016-05-19 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
CA2716109C (en) 2008-02-28 2016-07-19 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
ES2900353T3 (es) 2010-04-07 2022-03-16 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US8785650B2 (en) * 2012-03-30 2014-07-22 Dow Agrosciences, Llc. Methods for preparing 3-substituted-6-trifluoromethyl pyridines and methods for using 6-trichloromethyl halogenated pyridines
CA2930199C (en) 2013-11-12 2022-10-25 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
HUE055423T2 (hu) 2014-11-18 2021-11-29 Vertex Pharma Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére
KR101750453B1 (ko) 2015-09-11 2017-06-23 동아대학교 산학협력단 손잡이 세정이 가능한 샤워헤드용 방향제어밸브
US10399944B2 (en) 2017-08-10 2019-09-03 Janssen Pharmaceutica Nv Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists
US10590083B2 (en) 2017-08-10 2020-03-17 Janssen Pharmaceutica Nv Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists
US10336701B2 (en) 2017-08-10 2019-07-02 Janssen Pharmaceutica Nv Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1147068A (en) 1966-12-02 1969-04-02 Ici Ltd Phenyl-pyridine derivatives
GB9012017D0 (en) * 1990-05-30 1990-07-18 Ici Plc Fungicidal compounds
DE4315867A1 (de) * 1993-05-12 1994-11-17 Hoechst Ag 3-Chlorpyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Flüssigkristallmischungen
DE4323916A1 (de) 1993-07-16 1995-01-19 Basf Ag Substituierte 2-Phenylpyridine
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US5849758A (en) * 1995-05-30 1998-12-15 American Cyanamid Company Herbicidal 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines
DE19748439A1 (de) * 1997-11-03 1999-05-06 Hoechst Ag 1,6-Disubstituierte Naphthalinderivate und ihre Verwendung in flüssigkristallinen Mischungen
ATE307121T1 (de) 2000-02-16 2005-11-15 Neurogen Corp Substituierte arylpyrazine
AU4368001A (en) * 2000-03-16 2001-09-24 Neurogen Corporation 5-substituted arylpyrimidines

Also Published As

Publication number Publication date
SK15432003A3 (sk) 2004-05-04
EP1392302A1 (en) 2004-03-03
IL158958A0 (en) 2004-05-12
BR0209920A (pt) 2004-03-30
MXPA03010692A (es) 2004-07-01
JP2004531570A (ja) 2004-10-14
ECSP034860A (es) 2004-01-28
US20030152520A1 (en) 2003-08-14
CA2448198A1 (en) 2002-12-05
HUP0400316A2 (hu) 2005-02-28
HRP20031056A2 (en) 2005-08-31
TNSN03119A1 (en) 2005-12-23
NO20035183D0 (no) 2003-11-21
US20080107608A1 (en) 2008-05-08
PL367153A1 (en) 2005-02-21
WO2002096421A1 (en) 2002-12-05
KR20040015716A (ko) 2004-02-19
RU2003134010A (ru) 2005-05-20
US7223778B2 (en) 2007-05-29
IS7046A (is) 2003-11-20
AP2003002920A0 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
US20080107608A1 (en) 5-Substituted-2-Arylpyridines
JP6934261B2 (ja) Ｎ−（アザアリール）シクロラクタム−１−カルボキサミド誘導体、その製造方法および応用
KR102075886B1 (ko) 신규한 피라졸로[3,4-d]피리미딘 화합물 또는 그 염
TWI292758B (en) Substituted aryl 1,4-pyrazine derivatives
KR101530117B1 (ko) 야누스 키나제 억제제 화합물 및 방법
CN104703987B (zh) 具有咪唑并吡嗪酮骨架的pde9抑制剂
HRP20020747A2 (en) Substituted arylpyrazines
CN110546145B (zh) 一种氮杂芳基衍生物、其制备方法和在药学上的应用
NZ523526A (en) Diaryl piperazines as capsaicin receptor ligands
US6887875B2 (en) 2,5-diarypyrimidine compounds
RS61002B1 (sr) Formulacija rnk za imunoterapiju
JP2007534624A (ja) ビアリールピペラジニル−ピリジン類縁体
JP7114591B2 (ja) Ｇｓｋ－３阻害剤
US6943173B2 (en) 5-substituted 2-aryl-4-pyrimidinones
JP2006509729A (ja) Ｃｒｆ受容体モジュレータとしての５−置換−２−アリールピラジン類
AU4368001A (en) 5-substituted arylpyrimidines
AU2002314809A1 (en) 5-substituted-2-arylpyridines as CRF1 modulators